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ABSTRACT 
Objective. To evaluate the influence of the main immunological markers on the 
disease phenotype at diagnosis in a large international cohort of patients with primary 
SjS. 
Methods. The Big Data Sjögren Project Consortium is an international, multicentre 
registry created in 2014. As a first step, baseline clinical information from leading 
centers on clinical research in SjS of the 5 continents was collected. The centers shared 
a harmonized data architecture and conducted cooperative online efforts in order to 
refine collected data under the coordination of a big data statistical team. Inclusion 
criteria were the fulfilment of the 2002 classification criteria. Immunological tests were 
carried out using standard commercial assays  
Results. By January 2018, the participant centres had included 10500 valid patients 
from 23 countries. The cohort included 9806 (93%) women and 694 (7%) men, with a 
mean age at diagnosis of primary SjS of 53 years, mainly White (78%) and included 
from European countries (71%). The frequency of positive immunological markers at 
diagnosis was 79.3% for ANA, 73.2% for anti-Ro, 48.6% for RF, 45.1% for anti-La, 13.4% 
for low C3 levels, 14.5% for low C4 levels and 7.3% for cryoglobulins. Positive 
autoantibodies (ANA, Ro, La) correlated with a positive result in salivary gland biopsy, 
while hypocomplementemia and especially cryoglobulinemia correlated with systemic 
activity (mean ESSDAI score of 17.7 for cryoglobulins, 11,3 for low C3 and 9.2 for low 
C4, in comparison with 3.82 for negative markers). The immunological markers with a 
great number of statistically-significant associations (p<0.001) in the organ-by-organ 
ESSDAI evaluation were cryoglobulins (9 domains), low C3 (8 domains), anti-La (7 
domains) and low C4 (6 domains). 
Conclusion. We confirm the strong influence of immunological markers on the 
phenotype of primary SjS at diagnosis in the largest multi-ethnic international cohort 
ever analysed, with a greater influence for cryoglobulinemic-related markers in 
comparison with Ro/La autoantibodies and ANA. Immunological patterns play a central 
role in the phenotypic expression of the disease already at the time of diagnosis, and 
may guide physicians to design a specific personalized management during the follow-
up of patients with primary SjS.  
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INTRODUCTION 
Primary Sjögren syndrome (SjS) is a systemic autoimmune disease that mainly affects 
middle-aged women with a frequency in general population ranging between 0.01 and 
0.72% 1. Etiopathogenically, the disease targets the exocrine glands that are infiltrated 
by lymphocytes (focal sialadenitis)2. More than 95% of patients present with oral 
and/or ocular dryness3, although they may also develop a wide number of systemic 
(extraglandular) manifestations, which may be the first clinical manifestation of the 
disease 4.  
Patients with primary SjS produce a wide variety of circulating autoantibodies directed 
to antigens either nuclear or cytoplasmic; in some cases, the target antigen is present 
within specific tissues. B lymphocyte hyperactivation, the most typical 
immunopathogenic peripheral abnormality of primary SS, accounts for these 
autoantibodies5,6. Immunological markers play a central role not only in the diagnosis 
of the disease, but also in predicting their outcome as prognostic markers7. The key 
immunological markers are anti-Ro antibodies, as the most specific SjS-related 
autoantibody, and cryoglobulins and hypocomplementaemia, as the main prognostic 
markers8. Among the variety of immunological markers, rheumatoid factor (FR) and 
anti-La antibodies are found in nearly half the patients with primary SjS, and although 
are not included in the recent ACR/EULAR set of classification criteria9, they should 
clinically considered as key immunological markers of the disease10,11. Previous studies 
in large multicentre national registries have analysed the association between 
immunological markers and the clinical disease phenotype3,11–13, with heterogeneous 
results, although most identified patients carrying anti-Ro/La antibodies as the subset 
with the most clinically and immunologically “active” phenotype14. 
The objective of this study was to evaluate the influence of the main immunological 
markers on the disease phenotype at diagnosis in a large international cohort of 
patients with primary SjS. 
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METHODS 
Patients 
The Big Data Sjögren Project Consortium is an international, multicentre registry 
established in 2014 to take a “high-definition” picture of the main features of primary 
SjS following a worldwide data-sharing cooperative merging of pre-existing clinical SjS 
databases from leading centers on clinical research in SjS of the 5 continents (see 
reference 14 for additional methodological details15). The centers share a harmonized 
data infrastructure and conduct cooperative online efforts in order to refine already 
collected data in each center. Inclusion criteria were the fulfilment of the 2002 
classification criteria16. Exclusion criteria for considering SjS as a primary disease were 
chronic HCV/HIV infections, previous lymphoproliferative processes, and associated 
systemic autoimmune diseases. Diagnostic tests for SjS (ocular tests, oral tests and 
salivary gland biopsy) were carried out according to the recommendations of the 
European Community Study Group17. The study was approved by the Ethics Committee 
of the Coordinating Centre (Hospital Clinic, Barcelona, Spain, registry HCB/2015/0869). 
 
Definition of variables 
Disease diagnosis was defined as the time when the attending physician confirmed 
fulfilment of the 2002 criteria. At this time, the main features of the disease were 
retrospectively collected and analysed. The following clinical variables were selected in 
order to be harmonized and further refined: age, gender, ethnicity, country of 
residence, fulfilment of the 2002 criteria items, antinuclear antibodies, rheumatoid 
factor, C3 and C4 levels, cryoglobulins, and organ-by-organ ESSDAI scores. By January 
2018, the participant centres had included 10500 valid patients from 23 countries. 
Systemic involvement at diagnosis was retrospectively classified and scored according 
to the ESSDAI18, which evaluates 12 domains or organ systems, and clinESSDAI19, which 
evaluates the same domains but excluding the last (biological domain). Each domain is 
divided into 3-4 levels according to the degree of activity and scored as 0 (no activity), 
1 (low activity), 2 (moderate activity) or 3 (high activity). Immunological tests were 
carried out using standard commercial assays (>95% of cases), using indirect 
immunofluorescence to detect ANA, ELISA to detect Ro/La antibodies, nephelometry 
for measuring RF and complement levels, and serum cryoglobulins by standard 
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measure as previously described20. We divided the results obtained according to the 
following two immunological subsets: patients with autoantibodies (ANA, Ro, La) and 
those presenting with cryoglobulin-related markers (RF, complement levels, 
cryoglobulins). 
 
Statistical analysis 
Descriptive data are presented as mean and standard deviation (SD) for continuous 
variables and numbers and percentages (%) for categorical variables. The Chi-square 
test was used to study the association between immunological markers with gender, 
diagnostic tests for SjS and systemic involvement. T-test was used to compare the 
mean age at diagnosis. All significance tests were two-tailed. P-values were adjusted 
for multiple comparisons using the false discovery rate (FDR) correction and values of 
p < 0.001 were considered significant to avoid false positive significant results.  A 
heatmap was constructed to represent the association pattern between 
immunological markers and disease phenotype. All analyses were conducted using the 
R V.3.2.3 for Windows statistical software package (https://www.R-project.org/). 
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RESULTS 
The baseline characteristics of the cohort are summarized in Table 1. The cohort 
included 9806 (93%) women and 694 (7%) men (female: male ratio, 14:1), with a mean 
age at diagnosis of primary SjS of 53.1 (SD 14.1) years, mainly White (78%) and 
included predominantly from European countries (71%). Dry mouth was reported by 
9832 (94%) of patients, dry eyes by 9684 (92%), abnormal ocular tests in 8167/9745 
(84%), abnormal oral tests in 6373/8115 (78%) and positive salivary gland biopsy in 
6368/7777 (82%) patients. 
 
a) Phenotype of patients carrying autoantibodies 
ANA+ patients. ANA were tested in 9784 patients, and were positive in 7749 (79%). 
ANA-positive patients had a lower mean age at diagnosis (52 vs 56 yrs), a higher 
frequency of abnormal ocular tests (86% vs 82%), positive biopsy (84% vs 79%), mean 
ESSDAI score (6.7 vs 4.5) and a higher frequency of activity in the lymphadenopathy 
(10% vs 5%), articular (40% vs 35%), cutaneous (11% vs 4%), hematological (25% vs 
11%) and biological (57% vs 31%) ESSDAI domains in comparison with ANA-negative 
patients (Table 2). 
Ro+ patients. Ro autoantibodies were tested in 10417 patients and were positive in 
7617 (73%). Ro-positive patients had a lower mean age at diagnosis (52 vs 57 yrs), had 
a lower frequency of dry mouth (91% vs 95%) and dry eyes (92% vs 97%), a lower 
frequency of positive biopsy (74% vs 96%), a higher mean ESSDAI score (6.7 vs 4.7) and 
a higher frequency of activity in the constitutional (10% vs 7%), cutaneous (11% vs 5%), 
renal (5% vs 2%), hematological (26% vs 13%) and biological (58% vs 31%) ESSDAI 
domains in comparison with Ro-negative patients (Table 2). 
a3. La+ patients. La autoantibodies were tested in 10362 patients and were positive in 
4662 (45%). La-positive patients had a lower mean age at diagnosis (51 vs 54 yrs), had 
a higher frequency of ocular (86% vs 82%) and oral (81% vs 76%) diagnostic tests, a 
lower frequency of positive biopsy (73% vs 87%), a higher mean ESSDAI score (7.2 vs 
4.3) and a higher frequency of activity in the constitutional (11% vs 7%), 
lymphadenopathy (10% vs 8%), glandular (24% vs 19%), cutaneous (12% vs 7%), renal 
(6% vs 3%), muscular (3% vs 2%), hematological (28% vs 18%) and biological (65% vs 
40%) ESSDAI domains in comparison with La-negative patients (Table 2). 
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Ro/La combination patterns. The 3 different combination patterns of anti-Ro/La 
antibodies (isolated Ro, isolated La and combined Ro and La) were associated with 
differentiated phenotypes (Table 3). Patients with isolated La+ had the highest 
frequency of dry eye (p=0.001) and active glandular and muscular domains (p<0.001), 
while patients carrying both autoantibodies showed the highest frequency of 
abnormal ocular and oral (p<0.001) diagnostic tests, and the highest frequencies of 
systemic activity in the constitutional, lymphadenopathy, cutaneous, renal, 
hematological and biological ESSDAI domains (p<0.001). 
 
b) Phenotype of patients with cryoglobulin-related markers 
RF+ patients. RF was tested in 8758 patients and was positive in 4245 (48.5%). RF-
positive patients had a lower mean age at diagnosis (51 vs 54 yrs), had a higher 
frequency of abnormal ocular (88% vs 83%) and oral (82% vs 76%) tests, a higher mean 
ESSDAI score (7.3 vs 5.6) and a higher frequency of activity in the glandular (26% vs 
19%), articular (44% vs 37%), cutaneous (12% vs 8%), hematological (29% vs 18%) and 
biological (66% vs 39%) ESSDAI domains in comparison with RF-negative patients 
(Table 4). 
Cryoglobulinemic patients. Cryoglobulins were tested in 4732 patients, and were 
positive in 342 (7%). Cryoglobulinemic patients had a higher frequency of abnormal 
oral tests (87% vs 76%), a higher mean ESSDAI score (17.7 vs 7.2) and a higher 
frequency of activity in the constitutional (25% vs 11%), lymphadenopathy (23% vs 
10%), glandular (39% vs 28%), cutaneous (38% vs 11%), renal (15% vs 5%), muscular 
(8% vs 3%), PNS (24% vs 7%), CNS (6% vs 2%), hematological (44% vs 25%) and 
biological (91% vs 50%) ESSDAI domains in comparison with non-cryoglobulinemic 
patients (Table 4). 
C4 hypocomplementemic patients. C4 values were measured in 8556 patients and 
were low in 1234 (14%). C4-hypocomplementemic patients had a lower mean age at 
diagnosis (51 vs 53 yrs), had a lower frequency of positive biopsy (75% vs 81%), a 
higher mean ESSDAI score (9.2 vs 6.0) and a higher frequency of activity in the 
constitutional (13% vs 10%), lymphadenopathy (13% vs 8%), cutaneous (18% vs 9%), 
renal (7% vs 4%), PNS (12% vs 5%), hematological (37% vs 21%) and biological (85% vs 
47%) ESSDAI domains in comparison with C4-normocomplementemic patients (Table 
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4). 
C3 hypocomplementemic patients. C3 values were measured in 8573 patients and 
were low in 1146 (13%). C3-hypocomplementemic patients had a lower mean age at 
diagnosis (49 vs 53 yrs), had a lower frequency of dry mouth (89% vs 94%) and dry eyes 
(89% vs 92%), a higher mean ESSDAI score (11.3 vs 5.7) and a higher frequency of 
activity in the constitutional (17% vs 9%), lymphadenopathy (18% vs 8%), cutaneous 
(22% vs 8%), pulmonary (15% vs 10%), renal (11% vs 4%), PNS (14% vs 5%), CNS (3% vs 
2%), hematological (43% vs 21%) and biological (86% vs 48%) ESSDAI domains in 
comparison with C3-normocomplementemic patients (Table 4). 
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DISCUSSION 
In the three last internationally-accepted classification criteria for primary SjS9,16,17, 
autoantibodies have always been one of the included criteria and always the only 
laboratory criterion. However, the number of autoantibodies accepted as criteria has 
been reduced progressively. The 1993 European Criteria included 4 antibodies (ANA, RF, 
Ro/SS-A, and/or La/SS-B), the 2002 Criteria 2 (anti-Ro/SS-A and anti-La/SS-B) and the 
2016 ACR/EULAR, only one (Ro/SS-A)9,16,17, in the search for a significant improvement 
of sensitivity and especially specificity. However, the figures for sensitivity/specificity 
obtained in the three sets of criteria are quite similar (0.93/0.94 for the 1993 criteria, 
0.96/0.94 for the 2002 criteria, and 0.96/0.95 for the 2016 criteria). In contrast, other 
immunological markers (cryoglobulins, hypocomplementemia) that are strongly 
associated with disease prognosis and outcomes have been never included in the 
criteria. In this worldwide study, we have confirmed the close association of all these 
immunological markers with the phenotype of the disease at the time of diagnosis in 
the largest cohort of primary SjS patients ever studied. 
We found ANA in 80% of patients with primary SjS, and as much the immunological 
marker most frequently detected. ANA+ patients had a specific phenotype (older age at 
diagnosis, higher frequency of abnormal diagnostic tests, higher mean ESSDAI and a 
higher frequency of activity in the lymphadenopathy, cutaneous and laboratory-related 
domains) (Figure 1). Some of these features may be related to a late diagnosis (age, 
enhanced frequency of diagnostic and laboratory tests) in comparison with patients with 
negative ANA, who are often diagnosed earlier on the basis of systemic features and 
positive anti-Ro21 (nearly 10% of Ro+ patients may be ANA negative22). However, the 
figures for the main systemic features are quite similar to that found in patients with 
anti-Ro antibodies, suggesting that a positive ANA result does not add specific value to 
the phenotype observed in anti-Ro carriers. Probably, the key usefulness of testing ANA 
would be the early suspicion of the disease in non-specialized healthcare settings. Since 
ANA are the most frequent autoantibodies in primary SjS and their detection is 
overwhelmingly available in standard healthcare settings, a positive result in a patient 
presenting with sicca features could help primary care physicians and other specialists 
to suspect an autoimmune origin of sicca symptoms and therefore, to refer the patient 
to the autoimmune specialist to discard the disease.  
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We found anti-Ro antibodies in 73% of our patients, a figure very close to that found for 
ANA. This is a logical consequence of the strong weight of these autoantibodies in the 
classification criteria used (2002), as mandatory criteria together with salivary biopsy. 
Various studies have correlated the presence of anti-Ro with most of the SjS-related 
features, including parotidomegaly, lymphadenopathy, cutaneous vasculitis, neurologic 
disease and serologic hallmarks such as the presence of hypergammaglobulinemia, 
rheumatoid factor and cryoglobulins10. Our results confirm a specific phenotype 
consisting of patients diagnosed at younger age, with a lower frequency of sicca 
syndrome and positive salivary gland biopsy, and a higher frequency of activity in the 
constitutional, cutaneous and laboratory ESSDAI domains. A recent study by Quartuccio 
et al compared Ro/La+ and Ro/La- patients23 and found a younger age at diagnosis and 
a higher frequency of glandular swelling, purpura, leukopenia, lymphoma, low C3, low 
C4, hypergammaglobulinemia, rheumatoid factor and serum cryoglobulins in Ro/La+ 
patients, while we have recently reported that anti-Ro/SS-A and anti-La/SS-B antibodies 
were also associated with global systemic activity, especially anti-Ro/SS-A, whose 
positivity at diagnosis also correlated with a higher activity score in the articular, 
cutaneous and renal domains in a Spanish multicentre study3. 
Anti-La antibodies were detected in the 45% of our patients and overwhelmingly 
associated with the presence of anti-Ro antibodies (95% of cases). Probably for this 
reason, the phenotype of La carriers was very similar to that reported for Ro carriers. 
However, when we analysed the phenotype of Ro/La patients according to the different 
antibody combinations, we found that the most striking phenotypic differences were 
found in patients carrying the two antibodies in comparison with those who carried only 
a single antibody, with a higher frequency of abnormal diagnostic tests, the highest 
mean ESSDAI score among the three groups, and the highest frequency of systemic 
activity in nearly all the ESSDAI domains (especially in the constitutional, 
lymphadenopathy, cutaneous, renal and hematological domains) (Figure 1). In a 
previous study, Locht et al24 reported a higher frequency of internal organ involvement 
in patients carrying anti-La and anti-Ro in comparison with those carrying anti-Ro alone, 
and other studies also reported similar results25,26. In contrast, recent studies have 
reported a lower frequency of abnormal diagnostics tests (Schirmer test, UWSF and 
salivary gland biopsy) in isolated La carriers27,28. The influence of Ro/La on the 
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phenotypic expression of primary SjS at diagnosis could be driven by immunogenetic 
differences. The presence of these autoantibodies has been significantly linked with 
specific HLA-D epitopes (B1*03 and QB1*02, an association even more prominent and 
extended to QA1*0501 when patients were stratified according to the presence of 
La/SSB autoantibodies29, suggesting a similar (but not identical) genetic susceptibility for 
Ro and La carriers. 
Rheumatoid factor was detected in nearly half our patients, who also showed a specific 
phenotype consisting of a young age at diagnosis, a higher frequency of abnormal 
diagnostic tests, a high mean ESSDAI score, and a high frequency of systemic activity in 
the glandular, articular, cutaneous and hematological domains (Figure 1). Previous 
studies reported that RF has an independent association with the main clinical and 
immunological features of the disease10, and we found recently that RF was associated 
with a higher ESSDAI score both at diagnosis and at the end of follow-up30. Thus, RF 
detection in primary SjS is clinically useful, especially for the diagnosis of some subsets 
of patients with primary SS, such as those with extraglandular manifestations or with 
circulating cryoglobulins. 
Cryoglobulinemia had no influence on the glandular disease expression for both 
subjective and objective glandular features (except for an increased frequency of 
abnormal oral diagnostic tests), but play a key role in driving a multisystemic phenotype 
with statistically-significant higher frequencies in all ESSDAI domains but one (articular) 
(Figure 1). In fact, patients with cryoglobulinemia showed the highest mean ESSDAI 
among all the immunological subsets, being 4-fold higher than the mean score found in 
patients with no immunological markers and 3-fold higher than that found in ANA+ or 
Ro+ patients (Figure 2). This is closely related to the presence of a systemic vasculitic 
process, since although many patients with cryoglobulinemia remain asymptomatic, the 
percentage of patients with circulating cryoglobulins who develop vasculitic symptoms 
in primary SjS is 35%20. The presence of cryoglobulinemic vasculitis at the diagnosis of 
primary SS is independently associated with mortality, and is closely linked with a higher 
baseline ESSDAI score31.  
In previous studies in multicentre national cohorts, we found a significant association 
between low complement levels and the main systemic SS features, including both 
extraglandular disease (fever, articular involvement, cutaneous vasculitis, and 
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peripheral neuropathy) and immunological markers (cryoglobulinemia, rheumatoid 
factor)7,32, and recently Shiboski et al33 have reported that sicca patients with 
hypocomplementemia were 6 times more likely to progress to definite SjS. In addition, 
hypocomplementemia is also closely associated with the two main adverse outcomes of 
primary SS (lymphoma development and death)34, although two studies7,35 reported a 
predominant role for low C4. This study is the first to analyse separately the phenotype 
associated with either low C4 or low C3 values, and we found significant differences. 
Patients with C4-hypocomplementemia were older and had an enhanced frequency of 
positive salivary biopsy, while those with C3-hypocomplementemia were younger and 
had a lower frequency of sicca symptoms. Both subsets of patients showed higher mean 
ESSDAI scores (Figure 2) and a close association with systemic activity in the ESSDAI 
domains, although systemic activity was more pronounced in C3-hypocomplementemic 
patients (Figure 1). This is a new finding, in contrast with previous studies carried out in 
more geographically-homogeneous populations that showed a predominant role for 
low C4 levels. Probably, the different degree of association between 
hypocomplementemia and cryoglobulinemia (cryoglobulinemia is more frequently 
associated with consumption of C4 factor) could explain these differences with previous 
studies, since the frequency of cryoglobulinemia is strongly influenced by geographical 
and ethnicity determinants15. 
The results of this study, however, should be interpreted with caution, and some 
limitations should be pointed out. Studies including clinical big data may detect some 
differences which, although statistically significant, may not be relevant clinically, and 
further studies are necessary to confirm their clinical relevance in smaller, but more 
homogeneous, populations. This was the reason why we considered statistically-
significant p-values less than 0.001 after adjusting for multiple comparisons using the 
false discovery rate. The predominant presence of European patients could also limit 
the generalization of the results in other ethnic subpopulations less frequently reported. 
Other sources of heterogeneity may include the variable amount of missing data for 
some variables and the immunological assays used by the different centers, although all 
are commercial tests and more than 80% used the same technique (ELISA) to test for 
Ro/La autoantibodies and ANA were overwhelmingly tested for by indirect 
immunofluorescence. 
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In summary, we confirm a strong influence of immunological markers on the phenotype 
of primary SjS at diagnosis in the largest multi-ethnic international cohort ever analysed, 
with a greater influence for cryoglobulinemic-related markers in comparison with Ro/La 
autoantibodies and ANA. Immunological patterns play a central role in the phenotypic 
expression of the disease already at the time of diagnosis, and may guide physicians to 
design a specific personalized management during the follow-up of patients with 
primary SjS. 
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APPENDIX 1 
Members of the EULAR-SS Task Force Big Data Consortium:  
a) Members of the EULAR-SS Task Force 
P. Brito-Zerón, C. Morcillo (Autoimmune Diseases Unit, Department of Medicine, Hospital CIMA- Sanitas, Barcelona, 
Spain); P. Brito-Zerón, A. Flores-Chavez, M. Ramos-Casals (Sjögren Syndrome Research Group AGAUR, Laboratory of 
Autoimmune Diseases Josep Font, IDIBAPS-CELLEX, Department of Autoimmune Diseases, ICMiD, University of 
Barcelona, Hospital Clínic, Barcelona, Spain); N. Acar-Denizli (Department of Statistics, Faculty of Science and 
Letters, Mimar Sinan Fine Arts University, Istanbul, Turkey); F. Ng (Institute of Cellular Medicine, Newcastle 
University, Newcastle Upon Tyne, UK); M. Zeher, Ildike-Fanny Horvath (Division of Clinical Immunology, Faculty of 
Medicine, University of Debrecen, Debrecen, Hungary); A. Rasmussen, K. Sivils, H. Scofield (Arthritis and Clinical 
Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, USA); R. Seror, X. 
Mariette (Center for Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique – Hôpitaux de 
Paris, Hôpitaux Universitaires Paris-Sud, Le Kremlin-Bicêtre, Université Paris Sud, INSERM, Paris, France Paris, 
France); T. Mandl, P. Olsson (Department of Rheumatology, Malmö University Hospital, Lund University, Lund, 
Sweden); X. Li (Department of Rheumatology and Immunology, Anhui Provincial Hospital, China); C. Baldini 
(Rheumatology Unit, University of Pisa, Pisa, Italy); J.E. Gottenberg (Department of Rheumatology, Strasbourg 
University Hospital, Université de Strasbourg, CNRS, Strasbourg, France); D. Danda, P. Sandhya (Department of 
Clinical Immunology & Rheumatology, Christian Medical College & Hospital, Vellore, India); L. Quartuccio, L. 
Corazza, S De Vita (Clinic of Rheumatology, Department of Medical and Biological Sciences, University Hospital 
"Santa Maria della Misericordia", Udine, Italy);  R. Priori, E. Bartoloni (Department of Internal Medicine and Medical 
Specialties, Rheumatology Clinic, Sapienza University of Rome, Italy); G. Hernandez-Molina, J. Sánchez-Guerrero 
(Immunology and Rheumatology Department, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán. 
México City, Mexico); A.A. Kruize, E. van der Heijden (Department of Rheumatology and Clinical Immunology, 
University Medical Center Utrecht, Utrecht, The Netherlands); V. Valim (Department of Medicine, Federal University 
of Espírito Santo, Vitória, Brazil); M. Kvarnstrom, M. Wahren-Herlenius (Department of Medicine, Solna, Unit of 
Experimental Rheumatology, Karolinska Institutet, and Karolinska University Hospital, Stockholm); D. Sene (Service 
de Médecine Interne 2, Hôpital Lariboisière, Université Paris VII, Assistance Publique-Hôpitaux de Paris, 2, Paris, 
France); R. Gerli (Rheumatology Unit, Department of Medicine, University of Perugia, Italy); S. Praprotnik 
(Department of Rheumatology, University Medical Centre, Ljubljana, Slovenia); D. Isenberg (Centre for 
Rheumatology, Division of Medicine , University College London , UK); R. Solans (Department of Internal Medicine, 
Hospital Vall d'Hebron, Barcelona, Spain); M. Rischmueller, S. Downie-Doyle (Department of Rheumatology, School 
of Medicine, The University of Western Australia, Crawley, Australia); S-K. Kwok, S-H. Park (Seoul St. Mary's Hospital, 
The Catholic University of Korea, Seoul); G. Nordmark (Rheumatology, Department of Medical Sciences, Uppsala 
University, Uppsala, Sweden); Y. Suzuki, M. Kawano (Division of Rheumatology , Kanazawa University Hospital , 
Kanazawa , Ishikawa , Japan); R. Giacomelli, F. Carubbi (Clinical Unit of Rheumatology, University of l'Aquila, School 
of Medicine, L'Aquila, Italy); V. Devauchelle-Pensec, A. Saraux (Rheumatology Department, Brest University 
Hospital, Brest, France); M. Bombardieri, E. Astorri (Centre for Experimental Medicine and Rheumatology, Queen 
Mary University of London, UK); B. Hofauer, A. Knopf (Hals-Nasen-Ohrenklinik und Poliklinik, Technische Universität 
München, München, Germany); H. Bootsma, A. Vissink (Department of Rheumatology & Clinical Immunology, 
University of Groningen, University Medical Center Groningen, the Netherlands); J.G. Brun, D. Hammenfors 
(Department of Rheumatology, Haukeland University Hospital, Bergen, Norway); G. Fraile (Department of Internal 
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Medicine, Hospital Ramón y Cajal, Madrid, Spain); S. E. Carsons (Division of Rheumatology, Allergy and Immunology 
Winthrop-University Hospital, Stony Brook University School of Medicine, Mineola, NY, USA); T. A. Gheita, 
(Rheumatology Department, Kasr Al Ainy School of Medicine, Cairo University, Egypt); H.M. Khalil 
(Ophthalmology Department, Faculty of Medicine, Beni Suef University, Egypt); J. Morel (Department of 
Rheumatology, Teaching hospital and University of Montpellier, Montpellier, France); C. Vollenveider (German 
Hospital, Buenos Aires, Argentina); F. Atzeni (IRCCS Galeazzi Orthopedic Institute, Milan, Italy); S. Retamozo 
(Hospital Privado Universitario de Córdoba, Institute University of Biomedical Sciences University of Córdoba, 
Córdoba, Argentina; V. Moça Trevisano (Federal University of São Paulo, Sao Paulo, Brazil); B. Armagan, L. Kilic 
(Department of Internal Medicine, Hacettepe University, Faculty of Medicine, Ankara, Turkey); T. Nakamura 
(Department of Radiology and Cancer Biology, Nagasaki University Graduate School of Biomedical Sciences, 
Nagasaki, Japan); A. Sebastian, P. Wiland (Department of Rheumatology and Internal Medicine, Wroclaw Medical 
Hospital, Wroclaw, Poland); S. Pasoto (Rheumatology Division, Hospital das Clínicas da Faculdade de Medicina da 
Universidade de São Paulo USP, São Paulo, Brazil); B. Kostov, A. Sisó-Almirall (Primary Care Research Group, 
IDIBAPS, Centre d’Assistència Primària ABS Les Corts, CAPSE, Barcelona, Spain). 
 
b) Members of the French ASSESS Cohort 
J. Sibilia (Rheumatology Centre National de Référence des Maladies Auto-Immunes Rares, Institut National de la 
Santé et de la Recherche Médicale UMRS_1109, Fédération de Médecine Translationnelle de Strasbourg, Strasbourg 
University Hospital, Université de Strasbourg, Strasbourg, France); C. Miceli-Richard, G. Nocturne (Rheumatology, 
Bicetre Hospital, Institut National de la Santé et de la Recherche Médicale U-1012, Université Paris Sud, Assistance 
Publique des Hôpitaux de Paris, Paris, France); J. Benessiano (Centre de Ressources Biologiques, Bichat Hospital, 
Assistance Publique des Hôpitaux de Paris, Paris, France); P. Dieude (Rheumatology, Bichat Hospital, Assistance 
Publique des Hôpitaux de Paris, Paris, France); J-J. Dubost (Rheumatology, Clermont-Ferrand Hospital, Clermont-
Ferrand, France); A-L. Fauchais (Internal Medicine, Limoges Hospital, Limoges, France); V. Goeb (Rheumatology, 
Amiens University Hospital, Amiens, France); E. Hachulla (Pierre Yves Hatron, Internal Medicine, Lille University 
Hospital, Lille, France); C. Larroche (Internal Medicine, Avicenne Hospital, Assistance Publique des Hôpitaux de 
Paris, Bobigny, France); V. Le Guern, X. Puéchal (Internal Medicine, Cochin Hospital, Assistance Publique des 
Hôpitaux de Paris, Paris, France); J. Morel (Rheumatology, Montpellier University Hospital, Montpellier, France);  
A. Perdriger (Rheumatology, Rennes University Hospital, Rennes, France); S. Rist, Rheumatology, Orléans Hospital, 
Orléans, France; O. Vittecoq (Rheumatology, Rouen University Hospital, Rouen, France); P. Ravaud (Centre of 
Clinical Epidemiology, Hotel Dieu Hospital, Assistance Publique des Hôpitaux de Paris, Institut National de la Santé 
et de la Recherche Médicale U378, University of Paris Descartes, Faculty of Medicine, Paris, France). 
 
c) Members of the Spanish GEAS Cohort (SS Study Group, Autoimmune Diseases Study Group GEAS, Spanish 
Society of Internal Medicine SEMI):  
B. Díaz-López (Department of Internal Medicine, Hospital Universitario Central de Asturias, Oviedo), C. Feijoo, 
(Department of Internal Medicine, Hospital Parc Taulí, Sabadell), L. Pallarés (Department of Internal Medicine, 
Hospital Son Espases, Palma de Mallorca), M. López-Dupla (Department of Internal Medicine, Hospital Joan XXIII, 
Tarragona), R. Pérez-Alvarez (Department of Internal Medicine, Hospital do Meixoeiro, Vigo), M. Ripoll (Department 
of Internal Medicine, Hospital Infanta Sofía, Madrid), B. Pinilla (Department of Internal Medicine, Hospital Gregorio 
Marañón, Madrid), M. Akasbi (Department of Internal Medicine, Hospital Infanta Leonor, Madrid), B. Maure 
(Department of Internal Medicine, Complejo Hospitalario Universitario, Vigo), E. Fonseca (Department of Internal 
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Medicine, Hospital de Cabueñes, Gijón), J. Canora (Department of Internal Medicine, Hospital Universitario de 
Fuenlabrada, Madrid), G de la Red (Department of Internal Medicine, Hospital Espíritu Santo, Barcelona), A.J. 
Chamorro (Department of Internal Medicine, Complejo Hospitalario de Ourense, Ourense), I. Jiménez-Heredia 
(Department of Internal Medicine, Hospital de Manises, Valencia, Spain), P. Fanlo (Complejo Universitario de 
Navarra), P. Guisado-Vasco (Hospital Quirón, Madrid), M. Zamora (Hospital Virgen de las Nieves, Granada). 
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FIGURE LEGENDS 
Figure 1. Heat map of the main statistically-significant associations (adjusted P-values < 
0.001) between immunological markers and disease phenotype.  
Figure 2. Mean ESSDAI score (2a) and clinESSDAI score (2b) according to each 
immunological marker. 
 
 
